Tag:
Immunomedics
Latest Headlines
Latest Headlines
Immunomedics promotes 2 cancer treatments to later-stage trials
Immunomedics ($IMMU) has generated mostly promising data from two new lymphoma treatments that use the company's "Dock-and-Lock" targeted drug delivery technology. The company describes the DNL tech,
FDA slams brakes on Immunomedics' cancer trial
Here's one way to threaten the timeline for a clinical study. The FDA has halted Immunomedics' ( $IMMU ) clinical trial of a therapy called clivatuzumab tetraxetan for pancreatic cancer because one
New lupus trial success ignites Immunomedics shares
Just weeks after Human Genome Sciences grabbed everyone's attention with the first-ever successful Phase III trial for lupus, Immunomedics and UCB have now unveiled promising mid-stage data for their
ZymoGenetics, Immunomedics shares rise on HGS lupus data
The prospect of a new lupus drug hitting the market after decades without a new treatment for the autoimmune disease obviously has Human Genome Sciences investors excited --the company's stock has
